Table 3.
Univariate analysis of overall survival.
| Characteristic | N | Median survival | 2-year survival | P1 |
|---|---|---|---|---|
| Treatment regimen | ||||
| Group 1 (Adjuvant TMZ only) | 21 | 15.6 months | 36% | 0.0495 |
| Group 2 (Concurrenent & adjuvant TMZ) | 22 | 25.5 months | 51% | |
| Age | ||||
| Age ≤ 50 years | 12 | -- Not met -- | 80% | 0.0299 |
| Age > 50 years | 31 | 16.9 months | 32% | |
| Resection status | ||||
| Biopsy | 11 | 10.3 months | 0% | |
| STR | 20 | 28.7 months | 53% | 0.00022 |
| GTR | 12 | 28.3 months | 60% | 0.43953 |
| KPS | ||||
| <70 | 13 | 15.6 months | 35% | 0.1212 |
| ≥70 | 30 | 23 months | 48% | |
| RPA class | ||||
| 3 | 6 | -- Not met -- | 80% | |
| 4 | 17 | 28.7 months | 63% | 0.0139 |
| 5 | 13 | 17.6 months | 23% | |
| 6 | 7 | 10.3 months | 14% | |
1
All p values derived from log-rank test.
2
Survival differences between biopsy, STR and GTR.
3
Survival difference between STR and GTR.